[
    {
        "title": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 1d",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=110C760F_3F9A_4220_AFA6_ECE3D0F1B517_153022.pdf",
        "date": "1d"
    },
    {
        "title": "Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Jun - Sun Pharma discontinues SCD-044 after Phase 2 trials failed efficacy endpoints in psoriasis and dermatitis.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f47dadb-ebba-4c16-b69b-2537b4b23507.pdf",
        "date": "3 Jun - Sun Pharma discontinues SCD-044 after Phase 2 trials failed efficacy endpoints in psoriasis and dermatitis."
    },
    {
        "title": "Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 May - Sun Pharma completes acquisition of Checkpoint Therapeutics, gaining FDA-approved UNLOXCYTTM oncology drug.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86b971af-7dee-4a2a-ac20-567a8f411d69.pdf",
        "date": "30 May - Sun Pharma completes acquisition of Checkpoint Therapeutics, gaining FDA-approved UNLOXCYTTM oncology drug."
    },
    {
        "title": "Compliances-Reg.24(A)-Annual Secretarial Compliance 30 May - Annual Secretarial Compliance Report with minor procedural deviation on related party transaction timing.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b94ac934-06a2-4cc7-b02e-f9cb9db1a0da.pdf",
        "date": "30 May - Annual Secretarial Compliance Report with minor procedural deviation on related party transaction timing."
    },
    {
        "title": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript 29 May - Q4 FY25: 9% sales growth, $100M Specialty investment, Checkpoint acquisition pending, final dividend Rs.5.50/share.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3466942d-443e-4c97-8148-54b3f242e619.pdf",
        "date": "29 May - Q4 FY25: 9% sales growth, $100M Specialty investment, Checkpoint acquisition pending, final dividend Rs.5.50/share."
    }
]